Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
Allopurinol Improves Diastolic Function in African Americans With Resistant Hypertension
VA Office of Research and Development
50 participants
Sep 30, 2024
INTERVENTIONAL
Conditions
Summary
African American adults in the United States have the highest prevalence rate of high blood pressure (hypertension) and heart failure in the world. African Americans with treatment resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to Caucasians. This trial will test if administration of the xanthine oxidase inhibitor - Allopurinol (commonly used in the treatment of gout), given over a period of 8 weeks, will improve heart function, exercise ability and quality of life in African American Veterans with resistant hypertension.
Eligibility
Inclusion Criteria5
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Veteran
- African American
- Resistant hypertension diagnosis (defined as blood pressure greater than 140/90 mmHg at 2 clinic visits despite the use of 3 antihypertensive medications at pharmacologically effective doses)
- Locale - Birmingham, AL and surrounding areas
Exclusion Criteria10
- History of heart failure
- Chronic kidney disease (estimated creatinine clearance \< 60 ml/min)
- Chronic steroid therapy
- Known coronary artery disease
- Known causes of secondary hypertension
- Already taking Allopurinol
- Magnetic Resonance Imaging Exclusion
- Claustrophobia
- Cardiac implantable electronic device (permanent pacemaker and/or intracardiac defibrillator)
- Metal clips and/devices or other item that specifically prohibit safe CMR
Interventions
Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then may be increased to 600mg/daily for an additional 4 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05888233